Genocea is a cutting-edge bioscience company based in Cambridge. Their mission is to leverage human biology to create cancer immunotherapies that cater to every patient's unique needs. They achieve this by unlocking the most crucial targets in the field.

At Genocea, their focus is on developing best-in-class, next-generation cancer immunotherapies. Their groundbreaking approach involves harnessing the potency of the immune system to identify the optimal targets for each individual patient. This personalized approach aims to deliver better outcomes, improved accessibility, and affordability.

Genocea's proprietary ATLAS™ technology lies at the heart of their breakthroughs. This clinically validated platform accurately selects therapeutically relevant antigens, which then drive robust anti-tumor immune responses. What sets ATLAS apart is its ability to identify Inhibigens™, which can reverse or dampen immune responses, providing a targeted and precise approach to cancer treatment.

With a dedicated management team, board of directors, and scientific advisory board, Genocea is committed to advancing the field of cancer immunotherapy. They continuously strive to innovate and revolutionize cancer treatment options for patients everywhere